



EPICS

CONGRESS COVERAGE: ESMO 2020 HIGHLIGHTS – GU MALIGNANCIES

September 2020

BACKGROUND



- > On September 23, 2020, following the European Society for Medical Oncology (ESMO) Virtual Congress, Aptitude Health brought together a group of scientists and clinical investigators with expertise in genitourinary (GU) malignancies to attend the Emerging Paradigms in Care Series (EPICS) Congress Coverage meeting
- > The goal of the expert panel was to critique and debate new evidence in GU cancers and gain strategic insight into the most impactful abstracts from the ESMO meeting with respect to shaping current research directions and/or changing the scope of practical clinical care

FACULTY EXPERTS




Chair Daniel Petrylak, MD





Karim Fizazi, MD, PhD



Leonard Gomella, MD



David Nanus, MD



Oliver Sartor, MD



Cora Sternberg, MD



Scott Tagawa, MD



AGENDA



Time EST	Topic	Speaker/Moderator
8.00 AM - 8.05 AM	Welcome and Introductions	Daniel Petrylak, MD
8.05 AM - 8.20 AM	Prostate Cancer – Cytotoxic, Hormonal, and Immune-Based Therapies	Oliver Sartor, MD
8.20 am – 8.35 am	Discussion: Prostate Cancer – Cytotoxic, Hormonal, and Immune-Based Therapies	All Moderator: Daniel Petrylak, MD
8.35 AM - 8.40 AM	Summary and Key Takeaways – Prostate Part 1	Oliver Sartor, MD
8.40 AM - 8.55 AM	Targeting Intracellular Signaling and DNA Damage Repair Pathways in Metastatic Prostate Cancer	Karim Fizazi, MD, PhD
8.55 AM — 9.10 AM	Discussion: Targeting Intracellular Signaling and DNA Damage Repair Pathways in Metastatic Prostate Cancer	All Moderator: Daniel Petrylak, MD
9.10 AM - 9.15 AM	Summary and Key Takeaways – Prostate Part 2	Karim Fizazi, MD, PhD
9.15 AM - 9.25 AM	Break	
9.25 AM - 9.40 AM	Renal Cell Carcinoma	David Nanus, MD
9.40 AM — 10.05 AM	Discussion: Renal Cell Carcinoma	All Moderator: Daniel Petrylak, MD
10.05 AM - 10.10 AM	Summary and Key Takeaways – RCC	David Nanus, MD
10.10 AM - 10.20 AM	Bladder Cancer – Immunotherapies	Cora Sternberg, MD
10.20 AM - 10.35 AM	Discussion: Bladder Cancer – Immunotherapies	All Moderator: Daniel Petrylak, MD
10.35 ам – 10.40 ам	Bladder Cancer – ADCs	Scott Tagawa, MD
10.40 AM - 10.50 AM	Discussion: Bladder Cancer – ADCs	All Moderator: Daniel Petrylak, MD
10.50 AM - 10.55 AM	Summary and Key Takeaways – Bladder Cancer	Cora Sternberg, MD
10.55 AM - 11.00 AM	Summary and Closing Remarks	Daniel Petrylak, MD





EPICS

Prostate Cancer – Cytotoxic, Hormonal, and Immune-Based Therapies

OLIVER SARTOR, MD

PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (1/5)



> Abstract 6110 – Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa):





PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (2/5)



> Abstract 609O - Results from a phase 1 study of AMG 160, a half-life extended (HLE), PSMA-





PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (3/5)



> Abstract 615MO – Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with





PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (4/5)



> Abstract 616MO - Efficacy of BN-brachyury (BNVax) + Bintrafusp alfa (BA) + N-803 in Castration-





PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: ABSTRACTS (5/5)



> Abstract 617MO – Repurposing Metformin as anticancer drug: Preliminary results of randomized





PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: DISCUSSION (1/3)



> The long-term OS data from STAMPEDE in both the higher- and lower-risk populations of patients with





PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: DISCUSSION (2/3)



> There are now a number of options that have been shown to improve OS in patients with CSPC





PROSTATE CANCER – CYTOTOXIC, HORMONAL, AND IMMUNE-BASED THERAPIES: DISCUSSION (3/3)



Novel agents (contd)









EPICS

Targeting Intracellular Signaling and DNA Damage Repair Pathways in Metastatic Prostate Cancer

KARIM FIZAZI, MD, PHD

TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: ABSTRACTS (1/3)

> Abstract 610O - Final overall survival (OS) analysis of PROfound: olaparib vs physician's choice of





TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: ABSTRACTS (2/3)

> Abstract 614MO - Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate





TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: ABSTRACTS (3/3)

> Abstract LBA4 – IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus





TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: DISCUSSION (1/3)

> The OS benefit seen in the PROfound trial with olaparib in HRR-altered mCRPC is viewed as very





TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: DISCUSSION (2/3)

> The data with ipatasertib + abiraterone in the IPATential150 trial are considered positive, but some





TARGETING INTRACELLULAR SIGNALING AND DNA DAMAGE REPAIR PATHWAYS IN METASTATIC PROSTATE CANCER: DISCUSSION (3/3)

> Experts found reassuring the retrospective data suggesting that cabazitaxel is effective regardless









EPICS

Renal Cell Carcinoma

DAVID NANUS, MD

RENAL CELL CARCINOMA: ABSTRACTS (1/6)



> Abstract 696O - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell





RENAL CELL CARCINOMA: ABSTRACTS (2/6)



> Abstract 702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for





RENAL CELL CARCINOMA: ABSTRACTS (3/6)



> Abstract LBA25 - Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and





RENAL CELL CARCINOMA: ABSTRACTS (4/6)



> Abstract 7000 – Kidney ccRCC Immune Classification (KIC) enhances the predictive value of T





RENAL CELL CARCINOMA: ABSTRACTS (5/6)



> Abstract 7010 – Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with





RENAL CELL CARCINOMA: ABSTRACTS (6/6)



> Abstract LBA26 – Phase 2 Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau (VHL)





RENAL CELL CARCINOMA: DISCUSSION (1/3)



> The combination of cabozantinib + nivolumab is likely to gain regulatory approval as a first-line therapy for mRCC on the basis of results from the CheckMate 9ER trial





RENAL CELL CARCINOMA: DISCUSSION (2/3)



> Atezolizumab in combination with cabozantinib is also perceived to have strong antitumor activity in





RENAL CELL CARCINOMA: DISCUSSION (3/3)



> Molecular biomarkers, including transcriptomics and IHC, are showing promise for identifying patients for IO









EPICS

Bladder Cancer – Immunotherapies

CORA STERNBERG, MD

BLADDER CANCER – IMMUNOTHERAPIES: ABSTRACTS (1/7)



> Abstract 6970 – A phase 3, randomized, open-label study of first-line durvalumab (D) with or





BLADDER CANCER – IMMUNOTHERAPIES: ABSTRACTS (2/7)



> Abstract LBA23 – Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L)





BLADDER CANCER – IMMUNOTHERAPIES: ABSTRACTS (3/7)



> Abstract 704MO – Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone





BLADDER CANCER – IMMUNOTHERAPIES: ABSTRACTS (4/7)



> Abstract 6990 – Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone





BLADDER CANCER – IMMUNOTHERAPIES: ABSTRACTS (5/7)



> Abstract LBA27 - Phase II multicenter, randomized study to evaluate efficacy and safety of





BLADDER CANCER – IMMUNOTHERAPIES: ABSTRACTS (6/7)



> Abstract 6980 – Patient-reported outcomes (PROs) from IMvigor130: a global, randomised,





BLADDER CANCER – IMMUNOTHERAPIES: ABSTRACTS (7/7)



> Abstract 705MO – Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical





BLADDER CANCER – IMMUNOTHERAPIES: DISCUSSION (1/3)



> Experts were surprised by the negative results of the KEYNOTE-361 trial evaluating





BLADDER CANCER – IMMUNOTHERAPIES: DISCUSSION (2/3)



> More effort is needed to identify biomarkers to differentiate patients with platinum-eligible mUC who





BLADDER CANCER – IMMUNOTHERAPIES: DISCUSSION (3/3)



> The results of the DANUBE trial, which did not meet either of the co-primary endpoints, are









EPICS

Bladder Cancer – ADCs

SCOTT TAGAWA, MD

BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: ABSTRACTS (1/3)



> Abstract LBA24 - TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab





BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: ABSTRACTS (2/3)



> Abstract 746P – EV-201: Long-term results of enfortumab vedotin monotherapy for locally





BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: ABSTRACTS (3/3)



> Abstract 771P - Efficacy of enfortumab vedotin in populations of interest among patients with





BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: DISCUSSION (1/2)



> Data with EV and sacituzumab govitecan suggest remarkable consistency across early phase and





BLADDER CANCER – ANTIBODY-DRUG CONJUGATES: DISCUSSION (2/2)



> Experts found reassuring the retrospective data regarding patients treated with EV in a real-world










EPICS

Key Highlights and Strategic Takeaways

KEY HIGHLIGHTS AND STRATEGIC TAKEAWAYS







KEY HIGHLIGHTS AND STRATEGIC TAKEAWAYS



